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Abstract
Primary central nervous system (PCNS) lymphomas are rare disease entities, 
though the incidence is increasing due to various immunosuppressive situations. 
The brain, eyes, and the spinal cord could be affected without any systemic dis-
ease involvement. Untreated PCNS lymphoma has been a rapidly fatal course. 
However, combined modality treatments have positive impact on overall survival. 
Pretreatment plan is formed by evaluating the treatment options to be used, disease 
involvement, and individual comorbidity. The PCNS lymphomas are known to be 
very sensitive to irradiation and chemotherapy treatments. The treatment plan is also 
generated according to the neurological condition and functional status of patients. 
The mainstay of induction therapy has been high dose methotrexate administration 
for most patients. The addition of radiotherapy as a consolidation treatment increases 
progression-free survival. The use of reduced irradiation dose and different frac-
tionation schemes has been investigated in different studies to avoid the increased 
toxicity of high-dose whole-brain radiotherapy. High-dose chemotherapy, autologous 
hematopoietic cell transplantation, and whole-brain radiotherapy are alternative 
applications in patients with insufficient response to induction therapy. Stereotactic 
radiotherapy is another option in case of relapsed or refractory disease. Age and 
performance are also important indicators of survival and tumor progression.
Keywords: primary central nervous system lymphoma, radiotherapy,  
new techniques
1. Introduction
Primary central nervous system lymphomas (PCNSLs) are rare disease entities. 
The brain, eyes, and the spinal cord could be affected without any systemic disease 
involvement [1]. PCNSL is an uncommon subtype of extranodal non-Hodgkin 
lymphoma that accounts for ≈ 3–4% of newly diagnosed central nervous system 
tumors [2]. The overall incidence rate of PCNSL is 0.47 per 100.000 person-years. 
Its incidence has increased during the last 3 decades and has been reported in both 
immunocompromised and immunocompetent patients. Immunocompromised 
patients are affected at a younger age compared with immunocompetent patients. 
The incidence is significantly higher in males compared with females.
The most significant increase in the incidence rates for PCNSLs over time 
has occurred in the oldest adults (aged 75+ years) [3]. There is an increase in 
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incidence of PCNSLs in the elderly, and survival remains poor and is negatively 
dominated by factors associated with HIV infection and advanced age. Such 
changes were largely driven by PCNSL cases in men between the ages of 20 and 
64 years [4]. There has been an overall decline in incidence of PCNSL from 1998 
to 2008. Thus the trend has been attributed in large part to changes in HIV/AIDS 
incidence and management over the same time period. In contrast, the incidence 
rates continued to increase in women at all ages and men aged 65 and older 
(Figure 1).
In immunocompetent individuals, they occur at a median age of about 55 years 
[5]. The incidence of this tumor in immunocompetent individuals has risen three-
fold during the last decades from 0.027 to 0.075; 100.000 person. Immunodeficient 
individuals, especially patients with AIDS, transplant recipients, and patients with 
congenital immunodeficiencies are at increased risk of developing PCNSLs. In 
patients with such severe immunodeficiencies, survival is heavily influenced by the 
underlying disease [6]. Autoimmune diseases that predispose to lymphoma include 
rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, myasthe-
nia gravis, sarcoidosis, and vasculitis [6].
Presenting symptoms and signs vary, depending on the tumor location. 
Periventricular lesions and related symptoms are common in patients with primary 
cerebral lymphoma. The majority of the lesions are located in the periventricular 
area, whereas in a few, they are located in the supratentorial area. In about 60% 
of cases, PCNSLs originate from periventricular areas such as the thalamus, the 
basal ganglia, and the corpus callosum, which are followed by the frontal lobe, 
parietal lobe, temporal lobe, and occipital lobe (20, 18, 15, and 4%, respectively). 
Immunocompetent patients tend to present predominantly with solitary lesions in 
70% of cases, compared with 50% in AIDS patients [1].
2. Pathogenesis
The central nervous system normally lacks lymphoid aggregates. The cellular 
and molecular events leading to neoplastic lymphocytic infiltration of the central 
nervous system are seen in PCNSLs [7].
Figure 1. 
The incidence rates of PCNSLs by gender from 1973 to 2007 [4].
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Primary lymphoma of the central nervous system (CNS) is defined as diffuse 
large B cell lymphoma confined to the central nervous system. Morphology does 
not distinguish between PCNSLs and extra-cerebral DLBCL [7]. While most cases 
of PCNSLs are composed of aggressive lymphoma subtypes, a small number of 
patients show indolent CNS lymphomas. The median growth fraction is 4% [8]. 
Three major issues need to be addressed to understand the nature of PCNSLs and 
develop specific therapeutic regimens (Figure 2):
1. The histogenetic origin of the tumor cells.
2. The transforming events.
3. The role of the microenvironment of the CNS.
The underlying molecular pathogenesis of PCNSL has yet to be elucidated.
Because of the fact that PCNSL is closely associated with EBV infection in 
immunocompromised individuals, involving mechanisms in PCNSL development 
are directed toward the immunologic reactions against EBV infection. On the other 
hand, the EBV infected B cells are controlled by T cells in nonimmunocompromised 
individuals. Therefore, a decline in T cells leads to the proliferation and dissemination 
of abnormal B cells in immunodeficiency states [6]. In addition, occasionally, patients 
with EBV DNA in spinal fluid have PCNSL. But EBV DNA is often found together 
with other microbial findings in CSF of immunocompromised patients [9]. PCNSL 
may be a consequence of EBV-mediated clonal expansion and malignant transforma-
tion of B-lymphocytes, a process that may be regulated by immune mechanisms [10].
3. Clinical presentation
The location of the lymphoma in the CNS determines the clinical presentation. 
Presenting symptoms and signs vary, depending on the site of involvement PCNSL 
can manifest in the brain, its coverings, spinal cord, and the eye. Distinct clinico-
pathologic entities have been described. In a large series with immunocompetent 
Figure 2. 
Model of pathogenesis for PCNSLs. Schematic presentations of several pathways involved in the pathogenesis 
of PCNSLs, SHM, somatic hypermutation; ASHM, aberrant somatic hypermutation; and CSR, class switch 
recombination [7].
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patients with PCNSL, focal neurologic deficits were found to be the most common 
sign that was seen in 70% of patients. Other important complaints include neuro-
psychiatric symptoms, the signs of raised intracranial pressure such as headache, 
nausea, and vomiting, followed by seizures and ocular symptoms [1]. Presenting 
symptoms may include headaches, blurred vision, motor difficulties, and personality 
changes. Personality changes are most often associated with lesions of the frontal 
lobes, periventricular white matter, or corpus callosum. Visual hallucinations may 
result from infiltration of visual pathways or the brainstem or may result from ocular 
or leptomeningeal involvement. This may result in delayed diagnosis that usually 
prompts neurologic evaluation. Cranial neuropathies can occur as a result of either 
meningeal involvement, infiltration of the brainstem, or invasion of isolated cranial 
nerves or their roots. Headache, especially late, in the course of the disease, involving 
the leptomeninges may be indicative of increased intracranial pressure.
In primary leptomeningeal lymphoma, up to 40% of patients with cerebral 
PCNSL may have evidence of meningeal involvement at the time of diagnosis based 
on analysis and imaging. The frequency of meningeal dissemination (MD) in pri-
mary CNS lymphoma, its prognostic impact, and optimal management have yet to 
be defined. But involvement of the leptomeninges by high risk systemic lymphoma 
is also a common relapse pattern. On the other hand, primary leptomeningeal 
lymphoma without synchronous cerebral/spine or systemic disease is very rare, 
making up less than 10% of all cases of PCNSLs. MD was concluded in the case of 
cytological detection of lymphoma cells, or light-chain restricted B cell population 
demonstrated by immunocytology or flow cytometry, or existence of a dominant 
amplicon in PCR analysis, or clear evidence of MD on MRI [11].
Major patient’s characteristics and therapy did not significantly differ between 
patients with MD versus those without MD [12]. Progression-free survival (PFS) 
and overall survival (OS) were not significantly different in patients with MD 
versus without MD. Median OS, of MD+ and MD- patients, was 21.5 months versus 
24.9 months (p = 0.98) [12]. Primary leptomeningeal lymphoma is a rare form of 
primary CNS lymphoma. Patients usually present with multifocal symptoms, with 
evidence of leptomeningeal enhancement and diagnostic CSF analysis. Presenting 
symptoms are multifocal in 68%. The most common presenting signs are cranial 
neuropathies 58%, especially of eye movements and with cranial nerve VI palsy 
31%, presented with headache 44%. In another study, leptomeningeal enhance-
ment was seen in 74% and the CSF profile was abnormal in all cases. CSF cytology 
detected malignant lymphocyte in 67% [13].
The third process neurolymphomatosis (NL) is a rare clinical entity character-
ized by infiltration of peripheral nerves, nerve roots, plexus, or cranial nerves by 
malignant lymphocytes. Symptoms include loss of sensation or motor function, 
for example, weakness of the extremities [14]. These patients showed lymphoma-
tous cell invasion that was more prominent in the proximal portion of the nerve 
trunk and induced demyelination without macrophage invasion and subsequent 
axonal degeneration in the portion distal from the demyelination site [14]. NL is 
poorly localized severe pain in the absence of parenchymal lesions of the brain or 
spinal cord or obvious lymphoma in the CSF. The process frequently spares the 
meninges.
The International PCNSL Collaborative Group retrospectively analyzed 50 
patients assembled from 12 centers in 5 countries over a 16-year period. NL was 
related to NHL in 90%. It occurred as the initial manifestation of malignancy in 26% 
cases. The affected neural structures included peripheral nerves 60%, spinal nerve 
roots 48%, cranial nerves 46%, and plexus 40% with multiple site involvement 58%. 
CSF cytology was positive in 40% and nerve biopsy confirmed the diagnosis in 88%. 
Thus, instead of insufficient CSF cytology studies, could be nerve biopsy [15].
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4. Evaluation
The baseline evaluation of any newly diagnosed patient with PCNSL should 
include a comprehensive physical and neurologic examination. Age and perfor-
mance status are the two most widely documented prognostic variables and must be 
recorded in every patient. Evaluation of cognitive function is important at baseline, 
and follow-up assessments are critical both to determine the benefit of therapy as 
well as monitor for treatment-related neurocognitive decline.
4.1 Examination of disease extension
Before the initiation of therapy, a careful examination for the disease extension 
has to be carried out, in order to perform optimal treatment modality. The evalua-
tion processes of patients suspected of having PCNSL should include:
• Optimal imaging of the brain parenchyma requires a gadolinium enhanced MRI 
scan. Contrast enhanced CT scans may be substituted in patients in whom MRI is 
medically contraindicated (e.g., cardiac pacemaker) or unavailable. Involvement 
of the spinal cord parenchyma is sufficiently rare that gadolinium enhanced MRI 
of the total spine is warranted only in patients with spinal symptoms.
• All patients should have a lumbar puncture for CSF cytology unless medically 
contraindicated due to elevated intracranial pressure. CSF should be sampled 
before or 1 week after surgical biopsy to avoid false positive results. CSF 
protein levels should only be assessed on lumbar puncture samples because 
ventricular CSF has a lower normal value. Additional CSF studies that may 
be helpful include cell count, beta-2 microglobulin, immunoglobulin H gene 
rearrangement, and flow cytometry.
• A detailed ophthalmologic examination, including dilated fundus examina-
tion, should be done to exclude vitreous, retinal, or optic nerve involvement. 
Fluorescein angiography may be helpful to confirm lymphomatous involve-
ment of the retina.
• Testicular ultrasound may be considered in older men to exclude an occult 
testicular lymphoma metastatic to brain.
Complete systemic staging is warranted in every patient. CT scan of the chest, 
abdomen, and pelvis and bone morrow biopsy with aspirate are the recommended 
staging procedures. Body positron emission tomography imaging may be incorpo-
rated into the evaluation of systemic disease.
The diagnostic procedure of choice for PCNSL is a stereotactic needle biopsy 
because patients derive no clinical benefit from surgical resection, and deep seated 
nature of most lesions increases the risk of surgical complications. Histopathological 
diagnosis is strongly needed, because of the fact that some intracranial processes, 
such as multiple sclerosis, sarcoidosis, and occasional gliomas may mimic similar 
appearance and treatment response to corticosteroids [16]. In general, the use of 
corticosteroids prior to biopsy should be avoided, as these agents are lymphocyto-
toxic; a single injection is known to alter proper histopathological evaluation, and a 
short course of treatment may cause the tumor to disappear temporarily [17].
Whenever possible, the tumor should be characterized by immunophenotyping. 
Characterizing the basic molecular and genetic abnormalities of PCNSL will foster the 
future development and application of target specific therapies in this disease [16].
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5. Radiographic features
Contrast-enhanced MRI of the brain is the preferred imaging modality. The radio-
graphic lesion tends to be solitary nonhemorrhagic mass, situated in the deep white 
matter adjacent to the ventricular surface. The borders are sharply circumscribed 
and supratentorial location in the majority of lesions 87%, but may be ill defined in 
15% [1, 18]. Mass effect and tumor edema are seen in over half of the cases. Contrast 
enhancement is encountered in all lesions but ring enhancement is uncommon [18]. 
Lesions appear isodense to hyperdense on CT images and isointense to hypointense 
on T2-weighted MRI images and enhance homogeneously after contrast administra-
tion. Diffusion weighted MRI images, sensitive to the intracellular water of masses of 
lymphoma cells, are frequently abnormal. The role of positron emission tomography 
scans in diagnosis is unclear. In a study, baseline PET imaging demonstrated hyper-
metabolism consistent with aggressive lymphoma in 75% of patients [19]. PET scans 
can be used to distinguish glucose-absorbing neoplastic lesions from areas of radiation 
necrosis, infection, or inflammation, which may also enhance on conventional CT/
MRI [20]. Prompt initiation of therapy is important in patients with PCNSL. Intensive 
chemotherapy and immunotherapy in patients with PCNSL in study, treatment delay 
was the most important clinical variable associated with decreased survival, and its 
independent from baseline performance status or risk score [21].
6. Treatment of PCNSL
PCNSL tends to be highly sensitive to both radiation and selected chemothera-
peutic agents, which distinguishes it from most other malignant primary brain 
neoplasms. Surgery has a limited, mainly diagnostic role. Neurologic deficits and 
decreased functional status related to the tumor tend to improve rapidly with 
successful therapy, such as chemotherapy or radiation therapy. The disease can be 
exquisitely sensitive to glucocorticoids as well and patients will allow functional 
status particularly if they show an early response to steroids. Methotrexate (MTX), 
given at sufficiently high dose to penetrate the CNS, is the most active single agent 
against PCNSL identified. High dose intravenous MTX should therefore be the back-
bone of induction therapy in most patients. The goal of induction chemotherapy is 
a radiographic complete response, which can be achieved in over half of the patients 
with MTX-based therapy and is generally associated with superior outcomes. Most 
patients, even those in complete response do not achieve long-term disease control 
or survival with induction chemotherapy alone. The optimal consolidation therapy 
has not been established, however, and all strategies have the potential for increased 
toxicity. The three main consolidation approaches being explored include high dose 
chemotherapy with autologous hematopoietic cell transplant rescue, nonmyeloabla-
tive chemotherapy, and whole brain radiation therapy (WBRT).
High dose MTX-based chemotherapy is a standard component of initial therapy 
for PCNSL. The available data suggest that chemotherapy regimens that include 
high-dose systemic MTX are more effective against PCNSL than other regimens. 
WBRT may improve outcome, but is associated with increased risk for neurological 
side-effects in elderly patients [22]. The optimal high-dose MTX-based regimen for 
PCNSL is unknown, and there is variation in clinical practice. Most patients with 
a good performance status suggest using MTX-based combination regimen rather 
than MTX alone. Examples of reasonable regimens include MTX plus cytarabine, or 
temozolomide, or procarbazine, or vincristine. Rituximab is included in all regi-
mens, except in rare cases of CD 20 negative or T cell PCNSL. The goal of induction 
therapy is to achieve a complete radiographic response before proceeding with 
7The Role of Radiotherapy in the Treatment of Primary Central Nervous System Lymphomas
DOI: http://dx.doi.org/10.5772/intechopen.84432
consolidation therapy in eligible patients. Complete response is achieved in approxi-
mately 30 to 60% patients with high-dose MTX-based induction therapy. While 
high-dose MTX-based induction chemotherapy prolongs survival over WBRT 
alone, at least half of the patients with PCNSL who achieve a complete response will 
relapse within 5 years. This late relapse results from residual systemic malignant 
cell. WBRT remains an alternative consolidation approach in younger patients, 
particularly those with contraindications, which has been shown to improve PFS 
compared with induction chemotherapy alone. The consolidation approach in older 
adults, who are at increased risk for both relapse and toxicities of high dose chemo-
therapy and radiation, is unknown.
6.1 Radiation therapy
PCNSL is extremely sensitive to radiation therapy, but its use in the initial treat-
ment of PCNSL has waned overtime as chemotherapy-based induction regimens 
have been optimized. Phase III trial patients with newly diagnosed PCNSL were 
randomly assigned therapy to six cycles of chemotherapy alone (intravenous MTX+ 
Ifosfamide) or the same chemotherapy with WBRT (45 Gy in 1.5 Gy fractions) [23–25] 
(Figure 3). A total of 13% patients died during initial chemotherapy; 551 patients 
were enrolled and randomized, of whom 318 were treated per protocol of these, and 
90 patients had a major protocol violation. In the per protocol population, median 
overall survival was 32.4 months in patients receiving WBRT (n = 154) versus 
37.1 months in those not receiving WBRT (n = 164) HR: 1.06. Thus primary hypoth-
esis was not proven. Median progression-free survival was 18.3 months in patients 
receiving WBRT and 11.9 months in those not receiving WBRT. Treatment-related 
neurotoxicity in patients with sustained complete response was more common in 
patients receiving WBRT 49% by clinical assessment and 71% by neuroradiology 
than in those who did not 26% and 46% (Figure 4).
After a median follow up of 81.2 months, patients who received WBRT had a 
nonsignificant improvement in PFS (18.2 versus 11.9 month HR, 0.83) and sig-
nificant PFS from last HDMTX (25.5 versus 12 month, HR, 0.65, p = 0.001) but 
without OS prolongation (Figure 5).
This trial prospectively monitored Quality of Life (QoL), to determine whether 
WBRT might lead to quality of life relevant late neurotoxicity. In year 2 after ran-
domization, cognitive functioning and global health status were reduced in the early 
WBRT arm as compared to the no early WBRT arm. Also, fatigue, appetite loss, and 
Figure 3. 
The G-PCNSL-SG-1 trial. Abbreviations: WBRT: whole brain radiotherapy; HD-MTX: high-dose 
methotrexate; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; and 
HD-AraC: high-dose cytarabine. * Combined with ifosfamide 1.5 g/m2 daily, d3–5, since 2006 [23].
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hair loss were more intense in the early WBRT arm. Mini mental state examination 
testing revealed lower values (p = 0.002) in the early WBRT arm [25] (Figure 6).
As can be seen in Figure 6, G-PCNSL-SG-1 trial was the first PCNSL trial docu-
menting a negative influence of early WBRT on QoL parameters. A phase II study 
combined modality therapy, based on high dose MTX, results in improved survival 
outcomes in PCNSL. The risk of neurotoxicity for patients aged >60 years is unaccept-
able with this regimen (1 g/m2 MTX on days 1 and 8 followed by WBRT 45–50.4 Gy), 
although survival outcomes for patients aged >60 years were higher than in many 
other series [26]. At these studies and other demonstrations, the major drawback in the 
use of WBRT in conjunction with chemotherapy for patients with PCNSL is the high 
incidence of cognitive worsening and white matter damage [27–29]. Neurotoxicity 
may present as a rapidly progressive dementia that develops after a variable delay 
from the end of combined modality treatment. Also, the 5 year cumulative incidence 
of neurotoxicity was found to be increased over time [27]. Radiological examinations 
showed diffuse white matter disease as well as cortical-subcortical atrophy. Older age, 
mental status, changes at diagnosis, and radiotherapy predicted neurotoxicity [27].
Figure 4. 
Progression-free survival in the per-protocol and intention-to-treat populations by treatment group PP = per 
protocol. ITT = intention to treat. HR = hazard ratio [24].
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Different radiation field and reduced dose WBRT consolidation in responding 
patients have been explored in studies and appear to be associated with higher 
response and decreased neurotoxicity rates compared with higher dose WBRT 
[30–33]. An example of the impact on the outcome and neurologic performance of 
different radiation fields and doses was assessed in a study in which 33 patients with 
PCNSL who achieved complete response after MTX-containing chemotherapy were 
referred to consolidation WBRT [30]. The study demonstrated that higher irradia-
tion doses (≥40 Gy) were not associated with improved disease control compared 
to lower doses (30–36 Gy). Also, disease control does not significantly differ with 
regard to irradiation doses to the tumor bed, while functional impairment as 
assessed by mini mental status examination was significantly more common in 
patients treated with a WBRT dose ≥40 Gy. Thus, one can consider that consolida-
tion with WBRT 36 Gy is advisable in patients with PCNSL in complete response 
after HD-MTX based chemotherapy. Higher doses do not change the outcome and 
could increase the risk of neurotoxicity. The findings of this important study are 
illustrated in Figure 7 [30].
Figure 5. 
PFS from last high-dose methotrexate-based chemotherapy and overall survival analyzed as-treated in the 
ITT population. (A) Progression-free survival (PFS) from last high-dose methotrexate (HDMTX)-based 
chemotherapy (CHT) in patients with complete response (CR). (B) PFS from last HDMTX-based CHT in 
patients without CR. (C) Overall survival (OS) in patients with CR. (D) OS in patients without CR. The 
good outcome of the non-CR patients without further treatment can be explained by the fact that 6 of them 
probably did in fact have CR after HDMTX-based CHT. They were documented as having CR upon follow-up 
without further therapy. Moreover, one additional patient received whole-brain radiotherapy (WBRT) 
without progression 6 months after HDMTX-based CHT. CI = confidence interval; HR = hazard ratio; and 
ITT = intent-to-treat [25].
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As a different radiation fractionation, a phase I/II, NRG Oncology RTOG 0227 
study of MTX, Rituximab and Temozolomide, plus hyperfractionated WBRT 
(36 Gy in twice daily 1.2 Gy fractions) in 66 patients with PCNSL was associated 
with an objective response rate of 85.7%. This study demonstrated that OS and 
PFS were improved compared with historical controls from RTOG-9310. Among 
patients, 66% had grade 3 and 4 toxicities before hWBRT, and 45% of patients 
experienced grade 3 and 4 toxicities attributable to post hWBRT chemotherapy. 
Cognitive function and QoL improved or stabilized after hWBRT [31].
Other consecutive prospective studies, the R-MPV (rituximab, MTX, procarba-
zine, and vincristine) induction chemotherapy followed by consolidation reduced 
dose WBRT (23.4 Gy/ 1.8 Gy fraction), and cytarabine were found to be feasible 
and effective. In these studies, patients with ocular involvement were irradiated 
without orbital shielding to the full dose 23.4 Gy (patients in complete response) 
or to a dose of 36 Gy (patients with less than a complete response). Response rates 
were high (79% complete response) allowing a large proportion of patients to 
receive rdWBRT. These patients achieved durable disease control (2 year PFS 77%) 
associated with favorable neurocognitive outcomes. Median overall survival could 
not be reached (median follow-up for survivors, 5.9 years); 3 year OS was 87%. 
Cognitive assessments showed improvements in terms of executive function and 
verbal memory after chemotherapy [32, 33].
The mechanisms resulting in radiation-induced neurotoxicity remain to be clari-
fied. However, tissue oxidative stress, vasculopathy, demyelination, and depletion 
of progenitor oligodendroglial/neural stem cells have been postulated [34].
In addition to its ongoing role as an alternative to second line chemotherapy in 
younger patients who fail to achieve a complete response with first line systemic 
chemotherapy alone, WBRT is also a reasonable palliative option in patients who 
have contraindications to chemotherapy or relapsed, chemotherapy refractory 
disease.
Stereotactic radiotherapy may be an option for patients who have received 
WBRT. Prognosis is also influenced by therapy, which may include WBRT or stereo-
tactic radio surgery (SRS). In a study [35], patients who had recurred after WBRT 
were treated with salvage SRS. The study demonstrated acceptable local control and 
survival after SRS.
On the other hand, WBRT remains a reasonable salvage therapy in patients who 
have not responded adequately to induction chemotherapy. In addition, WBRT plus 
corticosteroids may be used for the palliation of patients who are not candidates 
Figure 6. 
Comparison of early-whole brain radiotherapy (WBRT) with no early-WBRT with regard to global 
health, cognitive-emotional-social functioning using the time course of median scores, interquartile ranges 
(IQR) for EORTC-QLQ-C30, BN20 dimensions, and the mini mental state examination (MMSE) of the 
G-PCNSL-SG-1 trial *p < 0.05. (A) scores for emotional and social functioning, (B) symptom scores and 
(C) Mini Mental State Examination (MMSE) [23].
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for chemotherapy. Complete responses can be obtained in most patients treated 
with standard fractionation to 20–40 Gy (for a 74% overall response rate). The 
median survival from initiation of WBRT was 16 months. The median time to 
PCNSL progression was 10 months. Treatment associated neurotoxicity is more 
common among those exposed to a total radiation dose >36 Gy, patients treated 
within 6 months of receiving MTX, and those older than 60 years of age [36, 37]. 
Treatment-related neurotoxicity was observed in 22% of patients. Salvage WBRT is 
effective for recurrent and refractory PCNSL.
7. Follow-up and monitoring
After completion of the initially planned treatment of PCNSL, patients should 
be evaluated to determine the disease response to treatment and should be followed 
longitudinally for relapse and long-term treatment toxicities.
Patients should be evaluated no more than 2 months after the completion of 
planned therapy to determine their response to treatment. Gadolinium-enhanced 
MRI scans are the standard for the evaluation of bulky parenchymal brain disease. 
Detailed ophthalmologic examination and lumbar puncture for cytology are 
required only if these studies were initially positive or if clinically indicated by new 
symptoms or sign. An interdisciplinary, international consensus group has devised 
the fallowing response criteria [16].
7.1 Response criteria
The following criteria were developed on the basis of anatomic and radiographic 
definitions.
Figure 7. 
Pattern of relapse according to radiation therapy fields and doses. Graphics at the left: patients treated with 
a WBRT dose of 30–36 Gy. Graphics at the right: patients treated with a WBRT dose 40 Gy. Upper graphics: 
patients treated without a tumor bed boost. Lower graphics: patients irradiated with a tumor bed boost. 
Symbols: ο = irradiated lesion in continuous CR; ● = relapsed lesion; ●==● = relapse with lesions both within 
and outside the boosted volume; ▲: = relapse in nonirradiated central nervous system areas (i.e., meninges and 
spinal cord); ♦ = systemic extra-central nervous system relapse. (Adopted from ref. [30]).
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Complete response requires the following:
1. Complete disappearance of all enhancing abnormalities on gadolinium-
enhanced MRI.
2. No evidence of active ocular lymphoma as defined by the absence of cells in the 
vitreous and resolution of any previously documented retinal or optic nerve 
infiltrate.
3. Negative CSF cytology. If the CSF is examined, patients with an Ommaya 
reservoir should have samples taken for the reservoir and lumbar puncture.
4. At the time a complete response is determined, the patient should have dis-
continued use of all corticosteroids for at least 2 weeks. Patients who met the 
criteria for CR may have the following features/limitations:
A. Any patient who otherwise meet all criteria for CR but needs steroid 
therapy should be regarded as unconfirmed CR.
B. Some patients will have a small but persistent enhancing abnormality on 
MRI related to biopsy or focal hemorrhage.
C. Patients with a persistent minor abnormality on fallow-up ophthalmologic 
examination.
Partial response (PR) was concluded for patients who met all of the following 
criteria: equal or more than 50% decrease in the contrast enhancing lesion that 
was seen on MRI compared to baseline imaging and a decrease in the vitreous cell 
count or retinal cellular infiltrate. PR was thought to be irrelevant to corticosteroid 
dose. CSF cytological examination may be negative or continue to show persistent 
malignant or suspicious cell providing no new sites of disease.
Progressive disease was defined as the following; more than 25% increase in the 
contrast enhancing lesion that was seen on MRI as compared to the best response, 
the progression of ocular disease, and the appearance of any new lesion.
Relapsed disease was considered as the appearance of any new lesion. Stable dis-
ease is that which does not meet the criteria for CR, CRu, PR, or progressive disease.
8. Prognosis
Untreated PCNSL has a rapidly fatal course, with survival of approximately 
1.5 month from the time of diagnosis. Survival increases with combined therapy. In 
population-based studies, among HIV uninfected cases, a 5-year survival increased 
from 19.1 (1992–1994) to 30.1% (2004–2006) [38]. Long-term survival is achieved 
in approximately 15–20% of patients treated with MTX-based therapy and radiation 
in contemporary clinical trial [39]. In a study on 41 patients treated with MATILDE 
chemotherapy regimen followed by WBRT, overall response rate was 76% after 
chemotherapy and 83% after chemotherapy plus radiotherapy. At a median follow-
up of 12 years, approximately 75% patients experienced an event, with a 5-year PFS 
of 24%. At 10 years from diagnosis, no patient showed chronic toxicities, with a 
mini-mental state examination score of ≥29 in all cases but one.
The most consistent prognostic factors are age and performance status. In order 
to adequately assess patients with disorder, standardized systems for prognosis have 
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been proposed [40]. Age, PS, LDH serum level, CSF protein concentration, and 
involvement of deep structures of brain were independent predictors of survival. 
A prognostic score including these 5 parameters seems advisable in distinguishing 
different risk groups in PCNSL. The 2 year OS is seen in 80% for patients with zero 
to one, 48% for patients with two to three, and 15% for patients with four to five 
unfavorable features.
9. Conclusion
Primary brain lymphoma is an uncommon variant of extranodal 
NHL. Therapeutic options include treatment with high dose MTX plus combined 
chemotherapy regimens and WBRT. Patients over age 60 generally succumb to a 
higher risk of treatment-related neurotoxicity. The optimal consolidation strategy 
in these patients has yet to be determined, and the best treatment modality should 
be individualized. By increasing the understanding of the molecular knowledge, 
and the clinical data originating from new researches, more effective treatment 
approaches and the best way to the integration of them into the treatment field of 
PCNSL would be determined.
Thanks
For the endless support, we are thankful to Medical Oncologist Ender KURT.
14
Brain and Spinal Tumors - Primary and Secondary
References
[1] Bataille B, Delwail V, Menet E, 
et al. Primary intracerebral malignant 
lymphoma: Report of 248 cases. Journal 
of Neurosurgery. 2000;92:261. DOI: 
10.3171/jns.2000.92.2.0261
[2] Hoffman S, Propp JM, McCarthy 
BJ. Temporal trends in incidence 
of primary brain tumors in the 
United States, 1985-1999. Neuro-
Oncology. 2006;8:27. DOI: 10.1215/
S1522851705000323
[3] Villano JL, Koshy M, Shaikh H, et al. 
Age, gender, and racial differences 
in incidence and survival in primary 
CNS lymphoma. British Journal of 
Cancer. 2011;105:1414. DOI: 10.1038/
bjc.2011.357
[4] O’Neill BP, Decker PA, Tieu C, 
Cerhan JR. The changing incidence 
of primary central nervous system 
lymphoma is driven primarily by the 
changing incidence in young and 
middle-aged men and differs from time 
trends in systemic diffuse large B-cell 
non-Hodgkin’s lymphoma. American 
Journal of Hematology. 2013;88:997. 
DOI: 10.1002/ajh.23551
[5] Herrlinger U, Schabet M, Clemens 
M, et al. Clinical presentation and 
therapeutic outcome in 26 patients 
with primary CNS lymphoma. Acta 
Neurologica Scandinavica. 1998;97:257. 
DOI: 10.1111/j.1600-0404.1998.
tb00647.x
[6] Bhagavathi S, Wilson JD. Primary 
central nervous system lymphoma. 
Archives of Pathology & Laboratory 
Medicine. 2008;132:1830. DOI: 
10.1043/1543-2165-132.11.1830
[7] Montesinos-Rongen M, Siebert R, 
Deckert M. Primary lymphoma of the 
central nervous system: Just DLBCL or 
not? Blood. 2009;113:7. DOI: 10.1182/
blood-2008-04-149005
[8] Jahnke K, Thiel E, Schilling A, et al. 
Low-grade primary central nervous 
system lymphoma in immunocompetent 
patients. British Journal of 
Haematology. 2005;128:616. DOI: 
10.1111/j.1365-2141.2004.05361.x
[9] Martelius T, Lappalainen M, 
Palomäki M, Anttila VJ. Clinical 
characteristics of patients with Epstein 
Barr virus in cerebrospinal fluid. BMC 
Infectious Diseases. 2011;11:281. DOI: 
10.1186/1471-2334-11-281
[10] Rock JP, Cher L, Hochberg FH, et al. 
Primary CNS lymphoma. In: Yomans 
JR, editor. Neurological Surgery. 4th 
ed. Philadelphia: WB Saunders; 1996. 
p. 2688
[11] Kiewe P, Fischer L, Martus P, et al. 
Meningeal dissemination in primary 
CNS lymphoma: Diagnosis, treatment, 
and survival in a large monocenter 
cohort. Neuro-Oncology. 2010;12:409. 
DOI: 10.1093/neuonc/nop053
[12] Korfel A, Weller M, Martus P, 
et al. Prognostic impact of meningeal 
dissemination in primary CNS 
lymphoma (PCNSL): Experience from 
the G-PCNSL-SG1 trial. Annals of 
Oncology. 2012;23:2374. DOI: 10.1093/
annonc/mdr627
[13] Taylor JW, Flanagan EP, O’Neill 
BP, et al. Primary leptomeningeal 
lymphoma: International primary 
CNS lymphoma collaborative group 
report. Neurology. 2013;81:1690. DOI: 
10.1212/01.wnl.0000435302.02895.f3
[14] Tomita M, Koike H, Kawagashira 
Y, et al. Clinicopathological features of 
neuropathy associated with lymphoma. 
Brain. 2013;136:2563. DOI: 10.1093/
brain/awt193
[15] Grisariu S, Avni B, Batchelor 
TT, et al. Neurolymphomatosis: 
An international primary CNS 
15
The Role of Radiotherapy in the Treatment of Primary Central Nervous System Lymphomas
DOI: http://dx.doi.org/10.5772/intechopen.84432
lymphoma collaborative group report. 
Blood. 2010;115:5005. DOI: 10.1182/
blood-2009-12-258210
[16] Abrey LE, Batchelor TT, Ferreri 
AJ, et al. Report of an international 
workshop to standardize baseline 
evaluation and response criteria for 
primary CNS lymphoma. Journal of 
Clinical Oncology. 2005;23:5034. DOI: 
10.1200/JCO.2005.13.524
[17] Porter AB, Giannini C, Kaufmann 
T, et al. Primary central nervous 
system lymphoma can be histologically 
diagnosed after previous corticosteroid 
use: A pilot study to determine whether 
corticosteroids prevent the diagnosis 
of primary central nervous system 
lymphoma. Annals of Neurology. 
2008;63:662. DOI: 10.1002/ana.21366
[18] Bühring U, Herrlinger U, Krings 
T, et al. MRI features of primary 
central nervous system lymphomas at 
presentation. Neurology. 2001;57:393. 
DOI: https://doi.org/10.1212/
WNL.57.3.393
[19] Mohile NA, Deangelis LM, Abrey LE.  
Utility of brain FDG-PET in primary 
CNS lymphoma. Clinical Advances in 
Hematology & Oncology. 2008;6:818
[20] Karantanis D, O’Neill BP, 
Subramaniam RM, et al. Contribution 
of F-18 FDG PET-CT in the detection 
of systemic spread of primary central 
nervous system lymphoma. Clinical 
Nuclear Medicine. 2007;32:271. DOI: 
10.1097/01.rlu.0000257269.99345.1b
[21] Rubenstein JL, Hsi ED, Johnson 
JL, et al. Intensive chemotherapy and 
immunotherapy in patients with newly 
diagnosed primary CNS lymphoma: 
CALGB 50202 (Alliance 50202). Journal 
of Clinical Oncology. 2013;31:3061. 
DOI: 10.1200/JCO.2012.46.9957
[22] Kasenda B, Ferreri AJ, Marturano E, 
et al. First-line treatment and outcome 
of elderly patients with primary 
central nervous system lymphoma 
(PCNSL)—A systematic review and 
individual patient data meta-analysis. 
Annals of Oncology. 2015;26:1305. DOI: 
10.1093/annonc/mdv076
[23] Herrlinger U, Schäfer N, Fimmers 
R, et al. Early whole brain radiotherapy 
in primary CNS lymphoma: Negative 
impact on quality of life in the 
randomized G-PCNSL-SG1 trial. 
Journal of Cancer Research and Clinical 
Oncology. 2017;143:1815. DOI: 10.1007/
s00432-017-2423-5
[24] Thiel E, Korfel A, Martus P, et al. 
High-dose methotrexate with or without 
whole brain radiotherapy for primary 
CNS lymphoma (G-PCNSL-SG-1): 
A phase 3, randomised, non-
inferiority trial. The Lancet Oncology. 
2010;11:1036. DOI: 10.1016/
S1470-2045(10)70229-1
[25] Korfel A, Thiel E, Martus P, 
et al. Randomized phase III study 
of whole-brain radiotherapy for 
primary CNS lymphoma. Neurology. 
2015;84:1242. DOI: 10.1212/
WNL.0000000000001395
[26] O’Brien PC, Roos DE, Pratt G, 
et al. Combined-modality therapy 
for primary central nervous 
system lymphoma: Long-term data 
from a phase II multicenter study 
(trans-Tasman radiation oncology 
group). International Journal of 
Radiation Oncology, Biology, 
Physics. 2006;64:408. DOI: 10.1016/j.
ijrobp.2005.07.958
[27] Omuro AM, Ben-Porat LS, Panageas 
KS, et al. Delayed neurotoxicity in 
primary central nervous system 
lymphoma. Archives of Neurology. 
2005;62:1595. DOI: 10.1001/
archneur.62.10.1595
[28] Schuurmans M, Bromberg JE, 
Doorduijn J, et al. Primary central 
nervous system lymphoma in the 
elderly: A multicentre retrospective 
Brain and Spinal Tumors - Primary and Secondary
16
analysis. British Journal of 
Haematology. 2010;151:179. DOI: 
10.1111/j.1365-2141.2010.08328.x
[29] Doolittle ND, Korfel A, Lubow 
MA, et al. Long-term cognitive 
function, neuroimaging, and quality 
of life in primary CNS lymphoma. 
Neurology. 2013;81:84. DOI: 10.1212/
WNL.0b013e318297eeba
[30] Ferreri AJ, Verona C, Politi LS, et al. 
Consolidation radiotherapy in primary 
central nervous system lymphomas: 
Impact on outcome of different fields 
and doses in patients in complete 
remission after upfront chemotherapy. 
International Journal of Radiation 
Oncology, Biology, Physics. 2011;80:169. 
DOI: 10.1016/j.ijrobp.2010.01.066
[31] Glass J, Won M, Schultz CJ, et al. 
Phase I and II study of induction 
chemotherapy with methotrexate, 
rituximab, and Temozolomide, 
followed by whole-brain radiotherapy 
and postirradiation temozolomide 
for primary CNS lymphoma: NRG 
oncology RTOG 0227. Journal of Clinical 
Oncology. 2016;34:1620. DOI: 10.1200/
JCO.2015.64.8634
[32] Morris PG, Correa DD, Yahalom 
J, et al. Rituximab, methotrexate, 
procarbazine, and vincristine followed 
by consolidation reduced-dose whole-
brain radiotherapy and cytarabine 
in newly diagnosed primary CNS 
lymphoma: Final results and long-
term outcome. Journal of Clinical 
Oncology. 2013;31:3971. DOI: 10.1200/
JCO.2013.50.4910
[33] Shah GD, Yahalom J, Correa DD, 
et al. Combined immunochemotherapy 
with reduced whole-brain radiotherapy 
for newly diagnosed primary CNS 
lymphoma. Journal of Clinical 
Oncology. 2007;25:4730. DOI: 10.1200/
JCO.2007.12.5062
[34] Omuro AM, Martin-Duverneuil 
N, Delattre JY. Complications of 
radiotherapy to the central nervous 
system. Handbook of Clinical 
Neurology. 2012;105:887-901. DOI: 
10.1016/B978-0-444-53502-3.00030-6
[35] Chao ST, Barnett GH, Vogelbaum 
MA, et al. Salvage stereotactic 
radiosurgery effectively treats 
recurrences from whole-brain radiation 
therapy. Cancer. 2008;113:2198. DOI: 
10.1002/cncr.23821
[36] Nguyen PL, Chakravarti A, 
Finkelstein DM, et al. Results of 
whole-brain radiation as salvage 
of methotrexate failure for 
immunocompetent patients with 
primary CNS lymphoma. Journal of 
Clinical Oncology. 2005;23:1507. DOI: 
10.1200/JCO.2005.01.161
[37] Hottinger AF, DeAngelis LM, 
Yahalom J, Abrey LE. Salvage whole 
brain radiotherapy for recurrent or 
refractory primary CNS lymphoma. 
Neurology. 2007;69:1178. DOI: 
10.1212/01.wnl.0000276986.19602.c1
[38] Shiels MS, Pfeiffer RM, Besson 
C, et al. Trends in primary central 
nervous system lymphoma incidence 
and survival in the U.S. British Journal 
of Haematology. 2016;174:417. DOI: 
10.1111/bjh.14073
[39] Ferreri AJ, Ciceri F, Brandes AA, 
et al. MATILDE chemotherapy regimen 
for primary CNS lymphoma: Results 
at a median follow-up of 12 years. 
Neurology. 2014;82:1370. DOI: 10.1212/
WNL.0000000000000314
[40] Ferreri AJ, Blay JY, Reni M, et al. 
Prognostic scoring system for primary 
CNS lymphomas: The international 
Extranodal lymphoma study group 
experience. Journal of Clinical 
Oncology. 2003;21:266. DOI: 10.1200/
JCO.2003.09.139
